Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer
The combination of abiraterone plus prednisolone appears to have similar efficacy and safety as enzalutamide in the treatment of patients with nonmetastatic castration-resistant prostate cancer, according to a study.
Abiraterone plus prednisolone, enzalutamide a toss-up in castration-resistant prostate cancer
21 Dec 2023
Somapacitan safe, effective in children with growth hormone deficiency
Use of somapacitan, a long-acting growth hormone (GH) derivative, for 2 years is efficacious and well tolerated in prepubertal children with GH deficiency (GHD), reports a study.
Somapacitan safe, effective in children with growth hormone deficiency
21 Dec 2023
Long-term risankizumab safe, effective in moderate-to-severe plaque psoriasis
Treatment with risankizumab in the long term shows lasting efficacy against moderate-to-severe plaque psoriasis and has good tolerability, according to the LIMMitless study.
Long-term risankizumab safe, effective in moderate-to-severe plaque psoriasis
20 Dec 2023
Add-on ribociclib continues to triumph in early breast cancer
Coming on the heels of the second interim analysis, the protocol-specified final invasive disease-free survival (iDFS) analysis of the phase III NATALEE trial continues to show a highly significant iDFS benefit with the combination of the CDK 4/6 inhibitor ribociclib and a nonsteroidal aromatase inhibitor (NSAI) in individuals with HR+/HER2- early breast cancer.
Add-on ribociclib continues to triumph in early breast cancer
20 Dec 2023
Most HF patients do not undergo loop diuretic dose reduction after SGLT2i initiation
Majority of the patients with heart failure (HF) who have initiated treatment with sodium-glucose cotransporter 2 inhibitor (SGLT2i) show no change in loop diuretic dose, reports a study.
